PDGFRB and neoplasm: TKIs, especially anti-angiogenesis-related TKI (VEGFR-TKI, PDGFR-TKI, etc.), profoundly modulate TME to undermine tumor cell viability, but TME remodeling sometimes promotes drug resistance.